Phase 3 study for ALS published in peer reviewed Muscle and Nerve publication
Pre-specified and post hoc analyses show NurOwn produced clinical benefits in ALS patients with less severe disease Biomarker data show that NurOwn drives significant changes in multiple ALS pathways and link its mechanism of action to its effect on disease progression Evidence presented across clinical and biomarker data suggests NurOwn has the potential to be a successful treatment for ALS
